Premium
Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma
Author(s) -
August Keith J.,
Farooki Sana,
Fulbright Joy M.,
August Amanda,
Portnoy Jay M.,
Pommert Lauren,
Burke Michael J.,
Guest Erin M.
Publication year - 2020
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.28021
Subject(s) - medicine , lymphoblastic lymphoma , asparaginase , desensitization (medicine) , lymphoblastic leukemia , lymphoma , adverse effect , oncology , leukemia , immunology , t cell , immune system , receptor
Hypersensitivity to pegaspargase is associated with inferior survival in pediatric patients with acute lymphoblastic leukemia and lymphoblastic lymphoma. In the past year, drug‐supply shortages have led to the lack of an available alternative to pegaspargase. Rather than omit asparaginase from the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma patients with hypersensitivity to pegaspargase, we continued pegaspargase treatments for nine pediatric patients, utilizing a rapid desensitization protocol. There were no adverse events related to the pegaspargase during desensitization, and all patients who were checked had asparaginase serum levels above the threshold of 0.1 IU/mL at 7 to 14 days after pegaspargase therapy.